Iovance Biotherapeutics Q3 2026: Record Revenue and a Shrinking Loss

As seen on the 24/7 Wall St. homepage on November 5, 2026.

IOVA Iovance Biotherapeutics
Q3 2026
EPS
-$0.05
est -$0.09 +41.4%
Revenue
$121M
est $115M +5.6%

Cash funds operations well into 2029, taking the usual biotech dilution worry off the table for now. Amtagvi demand narrowed the quarterly operating loss to $24.0 million from $94.9 million a year ago, and management reaffirmed full-year product revenue of $410 million to $420 million.

Continue ReadingShow less

Iovance Biotherapeutics posted Q3 2026 revenue of $121.47 million, an 80.1% jump from the same quarter a year earlier and ahead of expectations. The loss per share came in at $0.05, beating expectations and underscoring how quickly the company's cost structure is shifting as Amtagvi volume grows.

The headline driver was U.S. Amtagvi revenue of approximately $102 million, with Global Proleukin contributing roughly $20 million. Gross margin climbed to approximately 60%, up from 56% the prior quarter, reflecting both the higher Amtagvi volumes and ongoing manufacturing cost optimization at the company's internal cell therapy center.

The operating loss narrowed to $24.0 million in Q3 2026 from $94.9 million in Q3 2025, a swing of more than $70 million in a single year. That improvement came without any restructuring charges, compared to $5.1 million of such charges in the year-ago period.

Sponsored

Interim CEO Frederick Vogt noted that more than 1,000 patients have now been commercially treated with Amtagvi, and the company reaffirmed full-year 2026 total product revenue guidance of $410 million to $420 million. Management also said the authorized treatment center network has surpassed 100 sites across the U.S., Canada, and Australia, with at least 110 expected by year-end.

Cash on hand is expected to fund operations well into 2029, which removes near-term dilution risk from the conversation and lets investors focus on the commercial trajectory and the pipeline, which includes an sBLA submission planned in 2027 targeting non-small cell lung cancer, a setting the company estimates is about ten times the size of the advanced melanoma market where Amtagvi is already approved.

Mentioned: IOVA